Cadila Healthcare is currently trading at Rs. 315.15, up by 40.10 points or 14.58% from its previous closing of Rs. 275.05 on the BSE.
The scrip opened at Rs. 302.55 and has touched a high and low of Rs. 318.60 and Rs. 290.10 respectively. So far 555908 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 350.05 on 08-Apr-2019 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 318.60 and Rs. 248.25 respectively. The current market cap of the company is Rs. 32227.42 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.20% and 7.80% respectively.
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg. This medication is indicated for the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. The drug will be manufactured at the group’s formulation manufacturing facility at Baddi.
The group now has 284 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
